USFDA Approves Areva’s Furosemide HCl Injection USP for the US Market
Areva Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Furosemide HCl Injection, USP in 40mg/4mL Multiple-Dose Vials and 100mg/10ml. It is an AB-rated generic to Lasix™.
“Areva Pharmaceuticals is very pleased to announce the approval of Furosemide HCl. This critical need drug has seen an increased demand due to market shortages and Areva will be ready to meet the challenge. This approval further cements Areva’s commitment to alleviating the drug shortage crisis with sterile injectable products produced exclusively in the US and Europe,” says Irene Swaminathan, President & Chairwomen of Areva Pharmaceuticals.
Areva Pharmaceuticals’ Furosemide Injection will be available in cartons of 25 vials.
Furosemide injection USP
Furosemide is used to treat edema (fluid retention; excess fluid held in body tissues) caused by various medical problems, including heart failure, pulmonary edema (excess fluid in the lungs), kidney, and liver disease. Furosemide is in a class of medications called diuretics.
About Areva Pharmaceutical
Areva Pharmaceuticals Inc., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Areva ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most.